Casdatifan - Arcus Biosciences
Alternative Names: AB-521; HIF-2a inhibitor - Arcus BiosciencesLatest Information Update: 09 Jun 2025
At a glance
- Originator Arcus Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Renal cell carcinoma; Solid tumours
- Phase I Cancer
- No development reported Liver cancer
Most Recent Events
- 09 Jun 2025 AstraZeneca plans a phase Ib/III trial for Renal cell carcinoma (Late-stage disease, First-line therapy, Combination therapy, Metastatic disease)(PO), in July 2025 (NCT07000149)
- 28 May 2025 No recent reports of development identified for preclinical development in Liver-cancer in USA (IV)
- 28 May 2025 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in USA (IV)